Respiratory failure and hypoxemia in the cirrhotic patient including hepatopulmonary syndrome

Current Opinion in Anaesthesiology

Volumn 23, Issue 2, 2010, Pages 133-138

  Hemprich, Ulf ^a   Papadakos, Peter J ^a   Lachmann, Burkhard ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Hepatic hydrothorax; Hepatopulmonary syndrome; Liver transplantation; Portopulmonary hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

BLOOD GAS ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; ECHOGRAPHY; HEPATOPULMONARY SYNDROME; HIGH RISK PATIENT; HUMAN; HYDROTHORAX; HYPOXEMIA; INCIDENCE; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SODIUM RESTRICTION; THORACOCENTESIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

ANOXIA; HEPATOPULMONARY SYNDROME; HOSPITAL MORTALITY; HUMANS; HYDROTHORAX; HYPERTENSION, PULMONARY; INTENSIVE CARE; LIVER CIRRHOSIS; RESPIRATORY INSUFFICIENCY;

EID: 77952180846     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328335f024     Document Type: Review

References (66)

1. Sood G, Fallon MB, McGuire BM. Utility of a dyspnea-fatigue index for screening liver transplant candidates for hepatopulmonary syndrome [abstract]. Hepatology 1998;28:2319.
2. Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome: a liver-induced lung vascular disorder. N Engl J Med 2008;358:2378-2387.
3. Fallon MB, Arguedas MR. Pulmonary manifestations of liver disease. In: Schiff ER, Sorrel MF, Maddarey WC, editors. Schiff's diseases of the liver. 10th ed. Lippincott, Williams & Wilkins; 2006. pp. 513-526.
4. Singh N, Gayowski T, Wagener MM, et al. Outcome of patients with cirrhosis requiring intensive care support: prospective assessment of predictors of mortality. J Gastroenterol 1998;33:73-79.
5. Kress JP, Rubin A, Pohlman AS, et al. Outcomes of critically ill patients denied consideration for liver transplantation. Am J Respir Crit Care Med 2000;162:418-423.
6. Aggarwal A, Ong JP, Younossi ZM, et al. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001;119:1489-1497.
7. Moreau R, Hadengue A, Soupison T. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med 1992;20:746-750.
8. Gildea TR, Cook WC, Arroglia AC. Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU. Chest 2004;126:1598-1603.
9. Kamath PS, Kim WR. The Model for End-stage Liver disease (MELD). Hepatology 2007;45:797-805.
10. Cholongital E, Senzolo M, Burroughs AK. Risk factors, sequential organ failure assessment and Model for End-stage Liver Disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006;23:883-893.
11. Goldfarb G, Poynard T. Efficiency of respiratory assistance in cirrhotic patients with liver failure. Intensive Care Med 1983;9:271-273.
12. Shellman RG, Fulkerson WJ, Delong E. Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit. Crit Care Med 1988;16:671-678.
13. Freeman RB, Gish RG, Harper A. Model for End-stage Liver Disease (MELD) exception guidelines: results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006;12: S128-S136.
14. Hoeper MM, Krowka MJ, Strassburg CP. Pulmonary hypertension and hepatopulmonary syndrome. Lancet 2004;363:1461.
15. Kennedy TC, Knudson RJ. Exercise aggregated hypoxemia and orthodeoxia in cirrhosis. Chest 1977;72:305.
16. Schenk P, Fuhrmann V, Madl C. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for aterial oxygenation and their clinical consequences. Gut 2002;51:853-859.
17. Bertheolot P, Walker JG, Reid L. Arterial changes in the lungs in cirrhosis of the liver-lung spider nevi. N Engl J Med 1966;274:291-298.
18. Agusti A G N, Roca J, Rodiguez-Roisin R. Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis. Am Rev Respir Dis 1989;139:485-491. (Pubitemid 19057430)
19. Gomez FP, Martinez-Palli G, Rodriguez-Roisin R. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 2004;40:660-666.
20. Fallon MB, Abrams GA, Luo B. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113:606-614.
21. Rolla G, Brussino L, Colagrande P. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1991;26:842-847.
22. Fallon M, Abrams G. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32:859-865.
23. Rodriguez-Roisin R, Krowka MJ. Is severe arterial hypoxemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Respir J 1994;7:839-842.
24. Fallon MB, Mulligan DC, Gisch RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl 2006;12(Suppl): S105-S107.
25. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005;41:1122-1129.
26. Lange PA, Stoller JK. The hepatopulmonary syndrome: effect of liver transplantation. Clin Chest Med 1996;17:115-123.
27. Scott V, Mira A, Kang Y. Reversibility of the hepatopulmonary syndrome by orthotopic liver transplantation. Transplant Proc 1993;25:1787-1789.
28. Schwarzenberg SJ, Freese DK, Regelmann WE. Resolution of severe shunting after liver transplantation. Chest 1993;103:1271-1273.
29. Fallon MB. Hepatopulmonary syndrome: more than just a matter of tone? Hepatology 2006;43:912-914.
30. Rich S, Dantzker D, Ayres S. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223. (Pubitemid 17137857)
31. Mantz FA, Craige E. Portal axis thrombosis with spontaneous portocaval shunt and resultant cor pulmonale. AMA Arch Pathol 1951;52:91-97.
32. Simmoneau G, Galie N, Domenigetthi G. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43: S5-S12.
33. McDonnell P, Toyce P, Hutchins G. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127:437-441.
34. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
35. Ramsay MA, Simpson B, Nguyen AT. Severe pulmonary hypertension in liver transplantation candidates. Liver Transpl Surg 1997;3:494-500.
36. Swanson KL, Krowka MJ. Screen for pulmonary hypertension, especially in liver transplantation candidates. Cleve Clin J Med 2008;75:121-136.
37. Higgenbottam T. Pathophysiology of pulmonary hypertension. Chest 1994;105:7S-12S.
38. Hongqun L, Lee SS. Cardiopulmonary dysfunction in cirrhosis. Hepatology 2000;14:600-608.
39. Lebrec D, Brenot F, Simonneau G. Pulmonary arterial hypertension in portal hypertension. Eur Respir J 1998;11:1153-1166.
40. Schraufnagel D, Kay J. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996;17:1-15.
41. Kawut S, Krowka MJ, Fallon MB. Clinical risk factors for portopulmonary hypertension. Hepatology 2008;48:196-203.
42. Krowka MJ, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10 year screening algorithm. Hepatology 2006;44:1502-1510.
43. Swanson KL, Krowka ML. Arterial oxygenation associated with portopulmonary hypertension. Chest 2002;121:1869-1875.
44. Colle I, Moreau R, Godinho E. Portopulmonary hypertension in candidates for liver transplantation: diagnosis at evaluation comparing Doppler echocardiography with cardiac catheterization and incidence on the waiting list. Hepatology 2003;37:401-409.
45. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28:203-218.
46. Krowka M, Plevak D, Findlay J. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
47. Krowka MJ, Mandell MS, Ramsay MA. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;2:174-182.
48. Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-1432.
49. Wells JT, Runo JR, Lucey MR. Portopulmonary hypertension (editorial). Hepatology 2008;48:13-15.
50. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin Pract Cardiovasc Med 2007;4:319-329.
51. Plotkin JS, Kuo PC, Johnson LB. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65:457-459.
52. Shapiro SM, Oudiz RJ, Cao T. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-349.
53. Minder S, Fischler M, Muellhaupt B. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004;24:703-707.
54. Halank M, Marx C, Miehlke S. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004;39:1222-1223. (Pubitemid 40074294)
55. Reichenberger F, Voswinckel R, Steveling E. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28:563-567.
56. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-128.
57. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004;20:271-279.
58. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997;17:227-232.
59. Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency. Crit Care Med 2006;34:225-231.
60. Serrat J, Roza JJ, Planella T. Hepatic hydrothorax in the absence of ascites: respiratory failure in a cirrhotic patient. Anesth Analg 2004;99:1803-1804.
61. Rubinstein D, McInnes IE, Dudley FJ. Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology 1985;88:188-191.
62. Lefton HB, Rosa A, Cohen M, et al. Diagnosis and epidemiology of cirrhosis. Med Clin North Am 2009;93:787-799.
63. Lazaridis KN, Frank JW, Kamath PS. Hepatic hydrothorax: pathogenesis, diagnosis, and management. Am J Med 1999;107:262-267.
64. Xiol X, Guardiola J. Hepatic hydrothorax. Curr Opin Pulm Med 1998;4:239-242.
65. Kiafar C, Gilani N. Hepatic hydrothorax: current concepts of pathophysiology and treatment options. Ann Hepatol 2008;4:313-320.
66. Liu LU, Haddadin HA, Bodian CA. Outcome analysis of cirrhotic patients undergoing chest tube placement. Chest 2004;126:142-148.